Kiniksa Pharmaceuticals/$KNSA
1D1W1MYTD1Y5YMAX
Capital at risk
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
- Ticker
- $KNSA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 366
- Headquarters
- London, United Kingdom
- Website
- www.kiniksa.com
KNSA Metrics
BasicAdvanced
$5.9B
75.89
$0.99
0.07
-
Price and volume
Market cap
$5.9B
Beta
0.07
52-week high
$82.94
52-week low
$35.20
Average daily volume
469K
Financial strength
Current ratio
3.904
Quick ratio
3.208
Long term debt to equity
0.007
Total debt to equity
0.014
Profitability
EBITDA (TTM)
102.041
Gross margin (TTM)
54.50%
Net profit margin (TTM)
9.59%
Operating margin (TTM)
11.92%
Effective tax rate (TTM)
29.40%
Revenue per employee (TTM)
$2,300,000
Management effectiveness
Return on assets (TTM)
8.05%
Return on equity (TTM)
14.04%
Valuation
Price to earnings (TTM)
75.886
Price to revenue (TTM)
6.811
Price to book
8.96
Price to tangible book (TTM)
9.17
Price to free cash flow (TTM)
31.322
Free cash flow yield (TTM)
3.19%
Free cash flow per share (TTM)
2.399
Growth
Revenue change (TTM)
58.85%
Earnings per share change (TTM)
1,399.63%
3-year revenue growth (CAGR)
44.13%
3-year earnings per share growth (CAGR)
-32.56%
What the Analysts think about KNSA
Analyst ratings (Buy, Hold, Sell) for Kiniksa Pharmaceuticals stock.
Analyst projections of the future price of Kiniksa Pharmaceuticals stock.
Bulls say / Bears say
Kiniksa’s blockbuster IL-1 inhibitor ARCALYST delivered Q2 2026 net product revenue of $243.6 million, a 55% annual increase, and management raised full-year ARCALYST guidance to $980 million–$995 million, up from $930 million–$945 million, underscoring robust commercial execution. (Investing.com)
The Phase 2/3 trial of KPL-387 in recurrent pericarditis reported an interim dose-focusing analysis demonstrating rapid and sustained reductions in pain and inflammation at the 300 mg subcutaneous monthly dose, supporting initiation of the pivotal Phase 3 PASTORALE trial now enrolling patients. (GlobeNewswire)
With $525.9 million in cash, cash equivalents, and short-term investments as of June 30, 2026, and no debt, Kiniksa has a strong balance sheet to fund late-stage development and continued commercial scale-up of ARCALYST. (TradingView)
KNSA shares trade at a steep trailing P/E of approximately 104x, potentially leaving little room for valuation support if growth moderates or pipeline catalysts slip. (SPZCO)
ARCALYST accounts for nearly all of Kiniksa’s revenue, exposing the company to concentration risk should competitor therapies, pricing pressures, or adverse data impact market share. (TradingView)
KPL-387’s Phase 3 PASTORALE trial and delayed Phase 2 data due in H2 2026 represent key execution milestones; any delay or underwhelming results could materially disrupt Kiniksa’s valuation given its reliance on pipeline progression. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
KNSA Financial Performance
Revenues and expenses
KNSA Earnings Performance
Company profitability
Upcoming events
No upcoming events
KNSA News
AllArticlesVideos
Funds containing KNSA
AllUSDEURGBP
Fund name | Fund size | $KNSA weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.37% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.37% |
iShares Healthcare Innovation£DRDR | £1B | 0.37% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.24% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.24% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.